GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » Forward Dividend Yield %

Sonoma Pharmaceuticals (STU:O8Z3) Forward Dividend Yield % : 0.00% (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Forward Dividend Yield %?

As of today (2024-06-19), the Forward Annual Dividend Yield of Sonoma Pharmaceuticals is 0.00%.

As of today (2024-06-19), the Trailing Annual Dividend Yield of Sonoma Pharmaceuticals is 0.00%.

STU:O8Z3's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.92
* Ranked among companies with meaningful Forward Dividend Yield % only.

Sonoma Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Sonoma Pharmaceuticals's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Forward Dividend Yield % falls into.



Sonoma Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Sonoma Pharmaceuticals  (STU:O8Z3) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Sonoma Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines